These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

941 related items for PubMed ID: 27455854

  • 1. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
    van Schaik IN, van Geloven N, Bril V, Hartung HP, Lewis RA, Sobue G, Lawo JP, Mielke O, Cornblath DR, Merkies IS, PATH study group.
    Trials; 2016 Jul 25; 17(1):345. PubMed ID: 27455854
    [Abstract] [Full Text] [Related]

  • 2. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.
    Mielke O, Bril V, Cornblath DR, Lawo JP, van Geloven N, Hartung HP, Lewis RA, Merkies ISJ, Sobue G, Durn B, Shebl A, van Schaik IN, PATH study group.
    J Peripher Nerv Syst; 2019 Mar 25; 24(1):72-79. PubMed ID: 30672067
    [Abstract] [Full Text] [Related]

  • 3. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.
    van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Mielke O, Durn BL, Cornblath DR, Merkies ISJ, PATH study group.
    Lancet Neurol; 2018 Jan 25; 17(1):35-46. PubMed ID: 29122523
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.
    Merkies ISJ, van Schaik IN, Léger JM, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Durn BL, Cornblath DR, De Bleecker JL, Sommer C, Robberecht W, Saarela M, Kamienowski J, Stelmasiak Z, Tackenberg B, Mielke O, PRIMA Trial Investigators and the PATH Study Group.
    J Peripher Nerv Syst; 2019 Mar 25; 24(1):48-55. PubMed ID: 30672091
    [Abstract] [Full Text] [Related]

  • 6. A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.
    Cornblath DR, Hartung HP, Katzberg HD, Merkies ISJ, van Doorn PA.
    J Peripher Nerv Syst; 2018 Jun 25; 23(2):108-114. PubMed ID: 29603842
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.
    Markvardsen LH, Sindrup SH, Christiansen I, Olsen NK, Jakobsen J, Andersen H, Danish CIDP and MMN Study Group.
    Eur J Neurol; 2017 Feb 25; 24(2):412-418. PubMed ID: 28000311
    [Abstract] [Full Text] [Related]

  • 9. IgPro20, the Polyneuropathy and Treatment with Hizentra® study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG.
    Berger M, Harbo T, Cornblath DR, Mielke O.
    Immunotherapy; 2018 Aug 25; 10(11):919-933. PubMed ID: 29764262
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy.
    Markvardsen LH, Harbo T, Sindrup SH, Christiansen I, Andersen H, Jakobsen J, Danish CIDP and MMN Study Group.
    Eur J Neurol; 2014 Dec 25; 21(12):1465-70. PubMed ID: 25041191
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Immune Globulin Subcutaneous (Human) 20% (Hizentra®): A Review in Chronic Inflammatory Demyelinating Polyneuropathy.
    Lamb YN, Syed YY, Dhillon S.
    CNS Drugs; 2019 Aug 25; 33(8):831-838. PubMed ID: 31347096
    [Abstract] [Full Text] [Related]

  • 18. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
    Markvardsen LH, Christiansen I, Jakobsen J.
    Transfusion; 2016 Oct 25; 56(10):2443-2448. PubMed ID: 27401495
    [Abstract] [Full Text] [Related]

  • 19. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years.
    Gentile L, Mazzeo A, Russo M, Arimatea I, Vita G, Toscano A.
    Sci Rep; 2020 May 13; 10(1):7910. PubMed ID: 32404895
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.